Table 1 Epidemiological and clinical characteristics of the population of patients with oropharyngeal carcinoma treated at our center between 2011 and 2021
From: 2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
Characteristics | No. of patients (%) | ||||
|---|---|---|---|---|---|
Total cohort | p16-positive | p16-negative | HPV-NA | ||
Number | 1365 | 605 | 725 | 35 | |
Age | Mean (years) | 61.7 | 61.9 | 61.7 | 58.3 |
Sex | Female | 291 (21.3%) | 130 (21.5%) | 154 (21.2%) | 7 (20%) |
Male | 1074 (78.7%) | 475 (78.5%) | 571 (78.8%) | 28 (80%) | |
Localization | Tonsillar fossa | 582 (42.6%) | 345 (57%) | 222 (30.6%) | 15 (42.9%) |
Tongue base | 583 (42.7%) | 244 (40.3%) | 324 (44.7%) | 15 (42.9%) | |
Soft palate | 131 (9.6%) | 9 (1.5%) | 118 (16.3%) | 4 (11.4%) | |
Pharyngeal wall | 69 (5%) | 7 (11.6%) | 61 (8.4%) | 1 (2.9%) | |
T classification (8th edition) | T1 | 203 (14.9%) | 116 (19.2%) | 84 (11.6%) | 3 (8.6%) |
T2 | 326 (23.9%) | 175 (28.9%) | 142 (19.6%) | 9 (25.7%) | |
T3 | 347 (25.4%) | 148 (24.5%) | 192 (26.5%) | 7 (20%) | |
T4 | 473 (34.7%) | 166 (27.4%) | 307 (42.3%) | 16 (45.7%) | |
N classification (7th edition) | N0 | 285 (20.9%) | 85 (14%) | 195 (26.9%) | 5 (14.3%) |
N1 | 191 (14%) | 91 (15%) | 97 (13.4%) | 3 (8.6%) | |
N2A | 88 (6.4%) | 57 (9.1%) | 27 (3.7%) | 4 (11.4%) | |
N2B | 372 (27.3%) | 198 (32.2%) | 167 (23%) | 7 (20%) | |
N2C | 311 (22.8%) | 115 (19%) | 186 (25.7%) | 10 (28.6%) | |
N3 | 118 (8.6%) | 59 (9.8%) | 53 (7.3%) | 6 (17.1%) | |
N classification (8th edition) | N0 | - | 85 (14%) | 195 (26.9%) | 5 (14.3%) |
N1 | - | 347 (57.4%) | 96 (13.2%) | - | |
N2 | - | 115 (19%) | - | - | |
N2A | - | - | 20 (2.8%) | - | |
N2B | - | - | 137 (18.9%) | - | |
N2C | – | - | 151 (20.8%) | - | |
N3 | - | 58 (9.6%) | - | - | |
N3A | - | - | 4 (5.5%) | - | |
N3B | - | - | 122 (16.8%) | - | |
M classification | M0 | 1299 (95.2%) | 586 (96.9%) | 681 (93.9%) | 32 (91.4%) |
M1 | 66 (4.8%) | 19 (3.1%) | 44 (6.1%) | 3 (8.6%) | |
TNM stage (7th edition) | Stage I | 57 (41.8%) | 15 (2.5%) | 42 (5.8%) | 0 |
Stage II | 77 (56.4%) | 23 (3.8%) | 52 (7.2%) | 2 (5.7%) | |
Stage III | 211 (15.5%) | 91 (15%) | 117 (16.1%) | 3 (8.6%) | |
Stage IVA | 767 (56.2%) | 381 (63%) | 371 (51.2%) | 15 (42.9%) | |
Stage IVB | 187 (13.7%) | 76 (12.6%) | 99 (13.7%) | 12 (34.3%) | |
Stage IVC | 66 (4.8%) | 19 (3.1%) | 44 (6.1%) | 3 (8.6%) | |
TNM stage (8th edition) | Stage I | - | 118 (19.5%) | 42 (5.8%) | - |
Stage II | - | 157 (26%) | 52 (7.2%) | - | |
Stage III | - | 311 (51.4%) | 115 (15.9%) | - | |
Stage IVA | - | - | 313 (43.2%) | - | |
Stage IVB | - | - | 159 (21.9%) | - | |
Stage IVC | - | - | 44 (6.1%) | - | |
Stage IV | - | 19 (3.1%) | - | ||
Performance status (WHO) | PS 0 | 1110 (81.3%) | 541 (89.4%) | 544 (75%) | 25 (71.4%) |
PS 1 | 173 (12.7%) | 47 (7.8%) | 120 (16.6%) | 6 (17.1%) | |
PS 2–4 | 75 (5.5%) | 15 (2.5%) | 56 (7.7%) | 4 (11.4%) | |
NA | 7 (0.5%) | 2 (0.3%) | 5 (0.7%) | 0 | |